Drug recall · April 13, 2022
Orphenadrine Citrate Extended-Release Tablets recall
Why: CGMP Deviations:Nitrosamine impurity (NMOA) above the acceptable daily limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Orphenadrine Citrate Extended-Release Tablets, USP 100 mg, Rx Only, 100 Tablets, Manufactured by Sandoz Inc., Princeton, NJ 08540 NDC 0185-0022-01.
- Lots / codes
Lot #: JX6411, JX6413, Exp. 05/2022 Lot #: KC0723,KC3303, Exp. 08/2022 Lot #: KE4348, KE7169,KE4349, Exp. 11/2022 Lot #: KL3199, KM0072,KS3939, Exp. 03/2023 Lot #: LA7704, LA7703,LA9243, Exp. 11/2023
- Quantity
- 7908 bottles(790,800 extended release tablets)
- Company
- Sandoz, Inc, Princeton, NJ
- Distribution
- Nationwide
- Initiated
- March 21, 2022 · Voluntary: Firm initiated
- Classified
- April 6, 2022
- Reported
- April 13, 2022
- Ended
- August 14, 2023
- How notified
- Press Release
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Orphenadrine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.